Skip to main content
Smart Investors Daily
EL

NYSE · ELAN

Elanco Animal Health Incorporated

Healthcare · Drug Manufacturers - Specialty & Generic

$26.70

Down-$0.41 (-1.54%)

Updated Nov 20, 2026, 1:47 AM

SID Score

6.3/10

Composite research score

Smart Money

58/100

Neutral

Market cap
10.58B
P/E ratio
293.94
Dividend yield
0.00%
52-week range
$19.40 – $27.98
Volume
5.78M
Avg. volume
5.48M

Price performance · ELAN

ELAN price history

1M range · 20 trading sessions · Daily adjusted prices

Prices through Nov 18, 2026

ELAN closed at $26.70 after 20 trading sessions, up 17.67% for the selected period.

Last close
$26.70
Period change
+17.67%
Period low
$22.52
Period high
$26.84
Daily close
View OHLC price history
ELAN OHLC price history, latest 40 sessions
DateOpenHighLowCloseVolume
Nov 18, 2026$25.31$27.015$25.31$26.705.78M
Nov 17, 2026$26.32$26.80$25.74$25.853.84M
Nov 16, 2026$26.67$26.94$26.34$26.414.08M
Nov 13, 2026$26.70$26.91$26.22$26.785.38M
Nov 12, 2026$26.50$27.17$26.25$26.504.32M
Nov 11, 2026$26.55$26.76$26.13$26.483.78M
Nov 10, 2026$26.67$27.145$26.33$26.765.2M
Nov 9, 2026$26.19$27.2925$26.00$26.847.97M
Nov 6, 2026$24.065$26.26$23.97$25.7411.51M
Nov 5, 2026$25.24$25.24$23.43$23.686.71M
Nov 4, 2026$25.18$25.455$24.62$25.317.75M
Nov 3, 2026$24.23$24.815$24.07$24.576.46M
Nov 2, 2026$23.55$24.225$23.31$24.106.54M
Oct 30, 2026$23.48$23.48$22.93$23.063.45M
Oct 29, 2026$22.84$23.25$22.775$23.243.49M
Oct 28, 2026$22.75$22.92$22.56$22.654.39M
Oct 27, 2026$22.91$23.19$22.595$22.654.99M
Oct 26, 2026$22.62$23.095$22.18$22.964.21M
Oct 23, 2026$22.44$22.76$22.31$22.524.28M
Oct 22, 2026$22.43$22.8423$22.35$22.694.45M

Latest ELAN news

The latest Smart Investors Daily articles mentioning ELAN.

ELAN research

Overview

Company profile and research snapshot.

Company profile

Elanco Animal Health is an animal health company that is engaged in developing, manufacturing, and marketing pharma products for companion and food animals. It spun off from Eli Lilly in 2018 and acquired Janssen Animal Health in 2011, Novartis Animal Health in 2014, Boehringer Ingelheim Vetmedica in 2017, and Bayer Animal Health in 2020. The company's operations are conducted globally, and it sells its products in over 90 countries. It offers a range of food animal products used in cattle, sheep, goats, and swine production.

Visit company website

Analyst outlook

Consensus and target data currently published for this company.

Consensus
—
Average target
$24.75
Implied upside
—
Analysts
—
ELAN recent ratings
DateFirmRatingTarget
Nov 9, 2026JP MorganOverweight—
Oct 29, 2026Morgan StanleyEqual-Weight—
Oct 20, 2026JefferiesHold—
Oct 16, 2026Goldman SachsBuy—
Aug 6, 2026KeybancOverweight—
Open full forecast

News briefing

No generated briefing is available yet.

Yahoo · Nov 12, 2026

VETmAb Biosciences Appoints Katja Buhrer as Chief Operating Officer

SAN DIEGO, Nov. 12, 2026 (GLOBE NEWSWIRE) -- VETmAb Biosciences (VETmAb BIO), a clinical-stage biopharmaceutical company developing transformative biologics for pets, today announced the appointment of Katja Buhrer as Chief Operating Officer. Ms. Buhrer brings operational and strategic leadership experience across animal and human biotechnology, including as a senior executive at Kindred Biosciences (KindredBio), where she worked alongside members of VETmAb BIO’s founding team. Ms. Buhrer previo

AI research layers

Interpretive context generated from the platform’s current data sources.

No results

AI research layers have not been published yet.